Catalog No.: PC-72429Not For Human Use, Lab Use Only.
AXT107 (Gersizangitide) is a mimetic peptide derived from collagen IV, binds integrins αvβ3 and α5β1 (Kd=1.29 and 2.21 nM), disrupts VEGFR2-β3 complex formation.
AXT107 (Gersizangitide) is a mimetic peptide derived from collagen IV, binds integrins αvβ3 and α5β1 (Kd=1.29 and 2.21 nM), disrupts VEGFR2-β3 complex formation.
AXT107 inhibits VEGF-, HGF-, and PDGF-BB–stimulated phosphorylation of VEGFR2, c-Met, and PDGFRb receptors.
AXT107 also reduced total VEGFR2 levels by increasing internalization, ubiquitination, and degradation.
AXT107 suppressed subretinal neovascularization (NV) in two mouse models predictive of effects in neovascular age-related macular degeneration (NVAMD) and inhibited retinal NV in a model predictive of effects in ischemic retinopathies.
A combination of AXT107 and the current treatment aflibercept suppressed subretinal NV better than either agent alone.
AXT107 significantly reduced VEGF-induced vascular leakage by 86% at 1 month and 70% at 2 months in rabbit eyes, demonstrating the longer effectiveness than Aflibercept.
